{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:40:41Z","timestamp":1778564441890,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.3816\/ccc.2008.n.007","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:06:38Z","timestamp":1221080798000},"page":"48-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic\/Dermatologic Cooperation"],"prefix":"10.3816","volume":"7","author":[{"given":"Patrizia","family":"Racca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fanchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Caliendo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Ritorto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Volpatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Milanesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Ciorba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Paris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Facilissimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Macrip\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Clerico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libero","family":"Ciuffreda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2008.n.007_bib1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1634\/theoncologist.10-4-250","article-title":"Critical evaluation of current treatments in metastatic colorectal cancer","volume":"10","author":"Venook","year":"2005","journal-title":"The Oncologist"},{"key":"10.3816\/CCC.2008.n.007_bib2","first-page":"43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CCC.2008.n.007_bib3","unstructured":"Tumori.net Web site. Available at: http:\/\/www.tumori.net (Reparto Epidemiologia dei Tumori del Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute dell'Istituto Superiore di Sanit\u00e0). http:\/\/www.tumori.net. Accessed: July 14, 2007"},{"key":"10.3816\/CCC.2008.n.007_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11864-001-0068-7","article-title":"Metastatic colorectal cancer","volume":"2","author":"Kindler","year":"2001","journal-title":"Curr Treat Options Oncol"},{"key":"10.3816\/CCC.2008.n.007_bib6","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0959-8049(00)00150-7","article-title":"Therapeutic opportunities from tumour biology in metastatic colon cancer","volume":"36","author":"McLeod","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.3816\/CCC.2008.n.007_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2008.n.007_bib8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2008.n.007_bib9","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.3816\/CCC.2008.n.007_bib10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/annonc\/mdj084","article-title":"Cetuximab and irinotecan\/5-fluorouracil\/folinic acid is a safe combination for the first line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma","volume":"17","author":"Folprecht","year":"2006","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2008.n.007_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factorrelated peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.3816\/CCC.2008.n.007_bib12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0022-3565(24)29451-9","article-title":"Growth factor signaling in cell survival: implications for cancer treatment","volume":"298","author":"Talapatra","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3816\/CCC.2008.n.007_bib13","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1126\/science.1659742","article-title":"Growth factors and cancer","volume":"254","author":"Aaronson","year":"1991","journal-title":"Science"},{"key":"10.3816\/CCC.2008.n.007_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/bjc.1991.53","article-title":"The effects of intracolonic EGF on mucosal growth and experimental carcinogenesis","volume":"63","author":"Reeves","year":"1991","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2008.n.007_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0344-0338(11)80082-8","article-title":"Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases","volume":"189","author":"Karameris","year":"1993","journal-title":"Pathol Res Pract"},{"key":"10.3816\/CCC.2008.n.007_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ctrv.2003.10.003","article-title":"Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation","volume":"30","author":"Thomas","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CCC.2008.n.007_bib17","first-page":"1935","article-title":"Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck","volume":"59","author":"Huang","year":"1999","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2008.n.007_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/sj.onc.1202020","article-title":"Nuclear targeting of Bax during apoptosis in human colorectal cancer cells","volume":"17","author":"Mandal","year":"1998","journal-title":"Oncogene"},{"key":"10.3816\/CCC.2008.n.007_bib19","first-page":"1030","article-title":"Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis","volume":"62","author":"Wu","year":"2002","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2008.n.007_bib20","first-page":"2166","article-title":"Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis","volume":"6","author":"Huang","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2008.n.007_bib21","first-page":"1523","volume":"151","author":"Viloria-Petit","year":"1997","journal-title":"Am J Pathol"},{"key":"10.3816\/CCC.2008.n.007_bib22","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.007_bib23","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1200\/JCO.2004.00.117","article-title":"Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies","volume":"22","author":"Scartozzi","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.007_bib24","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during the therapy with antiepidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2008.n.007_bib25","first-page":"204","article-title":"Presence and intensity of the cetuximab-induced acne-rash predicts increased survival in studies across multiple malignancies","volume":"22","author":"Saltz","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2008.n.007_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11523-005-0001-2","article-title":"Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab. Clinical review","volume":"1","author":"Van Cutsem","year":"2006","journal-title":"Targ Oncol"},{"key":"10.3816\/CCC.2008.n.007_bib27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2006.04.062","article-title":"Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients","volume":"55","author":"Ro\u00e9","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CCC.2008.n.007_bib28","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with antiepidermal growth factor receptor antibody C335","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.3816\/CCC.2008.n.007_bib29","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1067\/mjd.2002.124621","article-title":"Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody","volume":"47","author":"Bouker","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CCC.2008.n.007_bib30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2004.06026.x","article-title":"Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours","volume":"151","author":"Jacot","year":"2004","journal-title":"Br J Dermat"},{"key":"10.3816\/CCC.2008.n.007_bib31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1610-0387.2005.05058.x","article-title":"The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies","volume":"3","author":"Segaert","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.3816\/CCC.2008.n.007_bib32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.3816\/CCC.2008.n.007_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","article-title":"HER1\/EGFR inhibitorassociated rash: future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum","volume":"10","author":"Perez-Soler","year":"2005","journal-title":"Oncologist"},{"key":"10.3816\/CCC.2008.n.007_bib34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/1523-1747.ep12264708","article-title":"Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages","volume":"83","author":"Nanney","year":"1984","journal-title":"J Invest Dermatol"},{"key":"10.3816\/CCC.2008.n.007_bib35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CCC.2008.n.007_bib36","first-page":"236","article-title":"The SERIES Clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors","volume":"4","author":"Lacouture","year":"2006","journal-title":"J Support Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811703978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811703978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:00:54Z","timestamp":1761519654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811703978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S1533002811703978"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2008.n.007","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic\/Dermatologic Cooperation","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2008.n.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}